nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—ALB—chronic obstructive pulmonary disease	0.241	1	CbGaD
Norethindrone—Danazol—Prednisone—chronic obstructive pulmonary disease	0.0523	0.137	CrCrCtD
Norethindrone—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0445	0.166	CbGbCtD
Norethindrone—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0445	0.166	CbGbCtD
Norethindrone—Cortisone acetate—Prednisone—chronic obstructive pulmonary disease	0.0441	0.115	CrCrCtD
Norethindrone—Cortisone acetate—Prednisolone—chronic obstructive pulmonary disease	0.043	0.112	CrCrCtD
Norethindrone—Fluoxymesterone—Prednisolone—chronic obstructive pulmonary disease	0.0384	0.1	CrCrCtD
Norethindrone—Progesterone—Prednisolone—chronic obstructive pulmonary disease	0.0374	0.0976	CrCrCtD
Norethindrone—Methyltestosterone—Prednisone—chronic obstructive pulmonary disease	0.0373	0.0975	CrCrCtD
Norethindrone—Methyltestosterone—Prednisolone—chronic obstructive pulmonary disease	0.0364	0.0951	CrCrCtD
Norethindrone—Testosterone—Prednisolone—chronic obstructive pulmonary disease	0.0324	0.0847	CrCrCtD
Norethindrone—Hydrocortisone—Prednisone—chronic obstructive pulmonary disease	0.0312	0.0815	CrCrCtD
Norethindrone—Hydrocortisone—Prednisolone—chronic obstructive pulmonary disease	0.0305	0.0796	CrCrCtD
Norethindrone—ALB—Prednisone—chronic obstructive pulmonary disease	0.0288	0.107	CbGbCtD
Norethindrone—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0284	0.106	CbGbCtD
Norethindrone—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0192	0.0715	CbGbCtD
Norethindrone—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0187	0.0696	CbGbCtD
Norethindrone—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0183	0.0682	CbGbCtD
Norethindrone—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0163	0.0608	CbGbCtD
Norethindrone—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0159	0.0595	CbGbCtD
Norethindrone—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0151	0.0562	CbGbCtD
Norethindrone—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00956	0.0357	CbGbCtD
Norethindrone—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00902	0.0337	CbGbCtD
Norethindrone—Anaphylactoid reaction—Aminophylline—chronic obstructive pulmonary disease	0.000795	0.00891	CcSEcCtD
Norethindrone—Menstruation irregular—Prednisolone—chronic obstructive pulmonary disease	0.000789	0.00884	CcSEcCtD
Norethindrone—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.000784	0.00879	CcSEcCtD
Norethindrone—Hirsutism—Prednisolone—chronic obstructive pulmonary disease	0.000751	0.00842	CcSEcCtD
Norethindrone—Pain in extremity—Tiotropium—chronic obstructive pulmonary disease	0.000725	0.00813	CcSEcCtD
Norethindrone—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.000721	0.00808	CcSEcCtD
Norethindrone—Optic neuritis—Prednisolone—chronic obstructive pulmonary disease	0.00071	0.00796	CcSEcCtD
Norethindrone—Mental disorder—Roflumilast—chronic obstructive pulmonary disease	0.000699	0.00783	CcSEcCtD
Norethindrone—Tension—Roflumilast—chronic obstructive pulmonary disease	0.000682	0.00764	CcSEcCtD
Norethindrone—Embolism—Prednisolone—chronic obstructive pulmonary disease	0.00068	0.00762	CcSEcCtD
Norethindrone—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.000675	0.00756	CcSEcCtD
Norethindrone—Dermatitis atopic—Prednisolone—chronic obstructive pulmonary disease	0.00059	0.00661	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.000587	0.00658	CcSEcCtD
Norethindrone—Menstruation irregular—Prednisone—chronic obstructive pulmonary disease	0.000573	0.00642	CcSEcCtD
Norethindrone—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000551	0.00617	CcSEcCtD
Norethindrone—Renal failure—Tiotropium—chronic obstructive pulmonary disease	0.000549	0.00616	CcSEcCtD
Norethindrone—Hirsutism—Prednisone—chronic obstructive pulmonary disease	0.000546	0.00612	CcSEcCtD
Norethindrone—Affect lability—Salbutamol—chronic obstructive pulmonary disease	0.000544	0.0061	CcSEcCtD
Norethindrone—Migraine—Salbutamol—chronic obstructive pulmonary disease	0.000544	0.0061	CcSEcCtD
Norethindrone—Mood swings—Salbutamol—chronic obstructive pulmonary disease	0.000524	0.00587	CcSEcCtD
Norethindrone—Acne—Prednisolone—chronic obstructive pulmonary disease	0.000519	0.00582	CcSEcCtD
Norethindrone—Optic neuritis—Prednisone—chronic obstructive pulmonary disease	0.000516	0.00578	CcSEcCtD
Norethindrone—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.000513	0.00575	CcSEcCtD
Norethindrone—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.000499	0.00559	CcSEcCtD
Norethindrone—Embolism—Prednisone—chronic obstructive pulmonary disease	0.000494	0.00554	CcSEcCtD
Norethindrone—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.000493	0.00553	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000489	0.00548	CcSEcCtD
Norethindrone—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000489	0.00548	CcSEcCtD
Norethindrone—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.000481	0.00539	CcSEcCtD
Norethindrone—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.00047	0.00527	CcSEcCtD
Norethindrone—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.000463	0.00519	CcSEcCtD
Norethindrone—Tension—Aminophylline—chronic obstructive pulmonary disease	0.000454	0.00509	CcSEcCtD
Norethindrone—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000453	0.00508	CcSEcCtD
Norethindrone—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00045	0.00505	CcSEcCtD
Norethindrone—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.00045	0.00504	CcSEcCtD
Norethindrone—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.000448	0.00502	CcSEcCtD
Norethindrone—Acute coronary syndrome—Arformoterol—chronic obstructive pulmonary disease	0.000445	0.00498	CcSEcCtD
Norethindrone—Acute coronary syndrome—Formoterol—chronic obstructive pulmonary disease	0.000445	0.00498	CcSEcCtD
Norethindrone—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.000442	0.00496	CcSEcCtD
Norethindrone—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.000442	0.00496	CcSEcCtD
Norethindrone—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.000442	0.00495	CcSEcCtD
Norethindrone—Mental disorder—Tiotropium—chronic obstructive pulmonary disease	0.00044	0.00493	CcSEcCtD
Norethindrone—Dermatitis atopic—Prednisone—chronic obstructive pulmonary disease	0.000429	0.0048	CcSEcCtD
Norethindrone—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.000426	0.00477	CcSEcCtD
Norethindrone—Hepatobiliary disease—Montelukast—chronic obstructive pulmonary disease	0.000418	0.00468	CcSEcCtD
Norethindrone—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000418	0.00468	CcSEcCtD
Norethindrone—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000407	0.00456	CcSEcCtD
Norethindrone—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000401	0.0045	CcSEcCtD
Norethindrone—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.000398	0.00446	CcSEcCtD
Norethindrone—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.000398	0.00446	CcSEcCtD
Norethindrone—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.000397	0.00445	CcSEcCtD
Norethindrone—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00039	0.00437	CcSEcCtD
Norethindrone—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00431	CcSEcCtD
Norethindrone—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.000382	0.00429	CcSEcCtD
Norethindrone—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000378	0.00424	CcSEcCtD
Norethindrone—Acne—Prednisone—chronic obstructive pulmonary disease	0.000377	0.00423	CcSEcCtD
Norethindrone—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000376	0.00421	CcSEcCtD
Norethindrone—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000375	0.0042	CcSEcCtD
Norethindrone—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000375	0.0042	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000369	0.00414	CcSEcCtD
Norethindrone—Thrombophlebitis—Prednisolone—chronic obstructive pulmonary disease	0.000366	0.0041	CcSEcCtD
Norethindrone—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.000366	0.0041	CcSEcCtD
Norethindrone—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000366	0.0041	CcSEcCtD
Norethindrone—Amenorrhoea—Prednisone—chronic obstructive pulmonary disease	0.000361	0.00405	CcSEcCtD
Norethindrone—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00036	0.00404	CcSEcCtD
Norethindrone—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000358	0.00401	CcSEcCtD
Norethindrone—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000357	0.00401	CcSEcCtD
Norethindrone—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000357	0.004	CcSEcCtD
Norethindrone—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.004	CcSEcCtD
Norethindrone—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000355	0.00398	CcSEcCtD
Norethindrone—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.000355	0.00398	CcSEcCtD
Norethindrone—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.000355	0.00398	CcSEcCtD
Norethindrone—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000347	0.00389	CcSEcCtD
Norethindrone—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000346	0.00388	CcSEcCtD
Norethindrone—Tension—Formoterol—chronic obstructive pulmonary disease	0.000346	0.00388	CcSEcCtD
Norethindrone—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000346	0.00388	CcSEcCtD
Norethindrone—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000345	0.00387	CcSEcCtD
Norethindrone—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000342	0.00384	CcSEcCtD
Norethindrone—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.00384	CcSEcCtD
Norethindrone—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000342	0.00383	CcSEcCtD
Norethindrone—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000337	0.00377	CcSEcCtD
Norethindrone—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000335	0.00375	CcSEcCtD
Norethindrone—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000333	0.00373	CcSEcCtD
Norethindrone—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00368	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Prednisolone—chronic obstructive pulmonary disease	0.000328	0.00367	CcSEcCtD
Norethindrone—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000327	0.00366	CcSEcCtD
Norethindrone—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.00362	CcSEcCtD
Norethindrone—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000322	0.00361	CcSEcCtD
Norethindrone—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000314	0.00352	CcSEcCtD
Norethindrone—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000312	0.0035	CcSEcCtD
Norethindrone—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000309	0.00346	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000308	0.00345	CcSEcCtD
Norethindrone—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.0003	0.00337	CcSEcCtD
Norethindrone—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.0003	0.00337	CcSEcCtD
Norethindrone—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00335	CcSEcCtD
Norethindrone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000299	0.00335	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000298	0.00334	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000298	0.00334	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000292	0.00327	CcSEcCtD
Norethindrone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000291	0.00327	CcSEcCtD
Norethindrone—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00322	CcSEcCtD
Norethindrone—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00322	CcSEcCtD
Norethindrone—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00322	CcSEcCtD
Norethindrone—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00322	CcSEcCtD
Norethindrone—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000283	0.00317	CcSEcCtD
Norethindrone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000282	0.00316	CcSEcCtD
Norethindrone—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00316	CcSEcCtD
Norethindrone—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00316	CcSEcCtD
Norethindrone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00313	CcSEcCtD
Norethindrone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00313	CcSEcCtD
Norethindrone—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000278	0.00312	CcSEcCtD
Norethindrone—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000276	0.00309	CcSEcCtD
Norethindrone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00307	CcSEcCtD
Norethindrone—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00304	CcSEcCtD
Norethindrone—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00304	CcSEcCtD
Norethindrone—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000267	0.003	CcSEcCtD
Norethindrone—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000266	0.00298	CcSEcCtD
Norethindrone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00296	CcSEcCtD
Norethindrone—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000263	0.00294	CcSEcCtD
Norethindrone—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00026	0.00292	CcSEcCtD
Norethindrone—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00026	0.00292	CcSEcCtD
Norethindrone—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.00287	CcSEcCtD
Norethindrone—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000256	0.00287	CcSEcCtD
Norethindrone—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000255	0.00286	CcSEcCtD
Norethindrone—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000253	0.00284	CcSEcCtD
Norethindrone—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000253	0.00284	CcSEcCtD
Norethindrone—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000252	0.00283	CcSEcCtD
Norethindrone—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00025	0.00281	CcSEcCtD
Norethindrone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00025	0.0028	CcSEcCtD
Norethindrone—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000249	0.00279	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00278	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00278	CcSEcCtD
Norethindrone—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000248	0.00278	CcSEcCtD
Norethindrone—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00278	CcSEcCtD
Norethindrone—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00278	CcSEcCtD
Norethindrone—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000246	0.00275	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00273	CcSEcCtD
Norethindrone—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00272	CcSEcCtD
Norethindrone—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.00271	CcSEcCtD
Norethindrone—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000241	0.0027	CcSEcCtD
Norethindrone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00024	0.00269	CcSEcCtD
Norethindrone—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000239	0.00268	CcSEcCtD
Norethindrone—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000239	0.00268	CcSEcCtD
Norethindrone—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00268	CcSEcCtD
Norethindrone—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000238	0.00267	CcSEcCtD
Norethindrone—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000238	0.00267	CcSEcCtD
Norethindrone—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000237	0.00265	CcSEcCtD
Norethindrone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000236	0.00264	CcSEcCtD
Norethindrone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00264	CcSEcCtD
Norethindrone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00264	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00263	CcSEcCtD
Norethindrone—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00262	CcSEcCtD
Norethindrone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00258	CcSEcCtD
Norethindrone—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000229	0.00256	CcSEcCtD
Norethindrone—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000229	0.00256	CcSEcCtD
Norethindrone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.00255	CcSEcCtD
Norethindrone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000227	0.00255	CcSEcCtD
Norethindrone—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000227	0.00254	CcSEcCtD
Norethindrone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000227	0.00254	CcSEcCtD
Norethindrone—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000225	0.00252	CcSEcCtD
Norethindrone—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000225	0.00252	CcSEcCtD
Norethindrone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000225	0.00252	CcSEcCtD
Norethindrone—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000224	0.00251	CcSEcCtD
Norethindrone—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000223	0.0025	CcSEcCtD
Norethindrone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000223	0.0025	CcSEcCtD
Norethindrone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00249	CcSEcCtD
Norethindrone—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.00022	0.00247	CcSEcCtD
Norethindrone—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000219	0.00246	CcSEcCtD
Norethindrone—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00245	CcSEcCtD
Norethindrone—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00242	CcSEcCtD
Norethindrone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00241	CcSEcCtD
Norethindrone—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.00238	CcSEcCtD
Norethindrone—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000212	0.00238	CcSEcCtD
Norethindrone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000212	0.00237	CcSEcCtD
Norethindrone—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000208	0.00233	CcSEcCtD
Norethindrone—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000206	0.00231	CcSEcCtD
Norethindrone—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000206	0.00231	CcSEcCtD
Norethindrone—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000204	0.00228	CcSEcCtD
Norethindrone—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000204	0.00228	CcSEcCtD
Norethindrone—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00227	CcSEcCtD
Norethindrone—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.0002	0.00225	CcSEcCtD
Norethindrone—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00224	CcSEcCtD
Norethindrone—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00223	CcSEcCtD
Norethindrone—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00218	CcSEcCtD
Norethindrone—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00215	CcSEcCtD
Norethindrone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00019	0.00213	CcSEcCtD
Norethindrone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00019	0.00213	CcSEcCtD
Norethindrone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000186	0.00209	CcSEcCtD
Norethindrone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00205	CcSEcCtD
Norethindrone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00205	CcSEcCtD
Norethindrone—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00203	CcSEcCtD
Norethindrone—Rash—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00203	CcSEcCtD
Norethindrone—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000181	0.00203	CcSEcCtD
Norethindrone—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000181	0.00203	CcSEcCtD
Norethindrone—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000181	0.00203	CcSEcCtD
Norethindrone—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00202	CcSEcCtD
Norethindrone—Headache—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00202	CcSEcCtD
Norethindrone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.00018	0.00201	CcSEcCtD
Norethindrone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00201	CcSEcCtD
Norethindrone—Rash—Montelukast—chronic obstructive pulmonary disease	0.000178	0.00199	CcSEcCtD
Norethindrone—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000177	0.00199	CcSEcCtD
Norethindrone—Depression—Prednisone—chronic obstructive pulmonary disease	0.000177	0.00198	CcSEcCtD
Norethindrone—Headache—Montelukast—chronic obstructive pulmonary disease	0.000177	0.00198	CcSEcCtD
Norethindrone—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000175	0.00196	CcSEcCtD
Norethindrone—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000174	0.00195	CcSEcCtD
Norethindrone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.00194	CcSEcCtD
Norethindrone—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00192	CcSEcCtD
Norethindrone—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000171	0.00192	CcSEcCtD
Norethindrone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00192	CcSEcCtD
Norethindrone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00192	CcSEcCtD
Norethindrone—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00017	0.00191	CcSEcCtD
Norethindrone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00188	CcSEcCtD
Norethindrone—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00185	CcSEcCtD
Norethindrone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00181	CcSEcCtD
Norethindrone—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.00016	0.0018	CcSEcCtD
Norethindrone—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00179	CcSEcCtD
Norethindrone—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000157	0.00176	CcSEcCtD
Norethindrone—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00175	CcSEcCtD
Norethindrone—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.00175	CcSEcCtD
Norethindrone—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000144	0.00161	CcSEcCtD
Norethindrone—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000141	0.00158	CcSEcCtD
Norethindrone—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000141	0.00158	CcSEcCtD
Norethindrone—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.00014	0.00156	CcSEcCtD
Norethindrone—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.00139	CcSEcCtD
Norethindrone—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.00012	0.00135	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00131	CcSEcCtD
Norethindrone—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.00129	CcSEcCtD
Norethindrone—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00127	CcSEcCtD
Norethindrone—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00127	CcSEcCtD
Norethindrone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00123	CcSEcCtD
Norethindrone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.00115	CcSEcCtD
Norethindrone—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000102	0.00115	CcSEcCtD
Norethindrone—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	9.97e-05	0.00112	CcSEcCtD
Norethindrone—Rash—Prednisolone—chronic obstructive pulmonary disease	9.82e-05	0.0011	CcSEcCtD
Norethindrone—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.81e-05	0.0011	CcSEcCtD
Norethindrone—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.76e-05	0.00109	CcSEcCtD
Norethindrone—Headache—Prednisolone—chronic obstructive pulmonary disease	9.76e-05	0.00109	CcSEcCtD
Norethindrone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	9.26e-05	0.00104	CcSEcCtD
Norethindrone—Nausea—Prednisolone—chronic obstructive pulmonary disease	9.25e-05	0.00104	CcSEcCtD
Norethindrone—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.99e-05	0.00101	CcSEcCtD
Norethindrone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	8.96e-05	0.00476	CbGpPWpGaD
Norethindrone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.95e-05	0.001	CcSEcCtD
Norethindrone—ALB—Platelet degranulation—TGFB2—chronic obstructive pulmonary disease	8.94e-05	0.00475	CbGpPWpGaD
Norethindrone—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	8.84e-05	0.0047	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	8.6e-05	0.00457	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—chronic obstructive pulmonary disease	8.52e-05	0.00452	CbGpPWpGaD
Norethindrone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	8.49e-05	0.00451	CbGpPWpGaD
Norethindrone—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.42e-05	0.00447	CbGpPWpGaD
Norethindrone—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	8.34e-05	0.000935	CcSEcCtD
Norethindrone—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.31e-05	0.00441	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.31e-05	0.00441	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.21e-05	0.00436	CbGpPWpGaD
Norethindrone—Asthenia—Prednisone—chronic obstructive pulmonary disease	8.12e-05	0.00091	CcSEcCtD
Norethindrone—Pruritus—Prednisone—chronic obstructive pulmonary disease	8.01e-05	0.000898	CcSEcCtD
Norethindrone—ALB—Platelet activation, signaling and aggregation—RAPGEF3—chronic obstructive pulmonary disease	7.96e-05	0.00423	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	7.91e-05	0.0042	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	7.84e-05	0.00417	CbGpPWpGaD
Norethindrone—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	7.53e-05	0.004	CbGpPWpGaD
Norethindrone—Dizziness—Prednisone—chronic obstructive pulmonary disease	7.49e-05	0.000839	CcSEcCtD
Norethindrone—ALB—Vitamin B12 Metabolism—CRP—chronic obstructive pulmonary disease	7.33e-05	0.00389	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	7.26e-05	0.00386	CbGpPWpGaD
Norethindrone—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.2e-05	0.000807	CcSEcCtD
Norethindrone—Rash—Prednisone—chronic obstructive pulmonary disease	7.14e-05	0.0008	CcSEcCtD
Norethindrone—Dermatitis—Prednisone—chronic obstructive pulmonary disease	7.13e-05	0.000799	CcSEcCtD
Norethindrone—Headache—Prednisone—chronic obstructive pulmonary disease	7.09e-05	0.000795	CcSEcCtD
Norethindrone—CYP3A7—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.9e-05	0.00367	CbGpPWpGaD
Norethindrone—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.83e-05	0.00363	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.81e-05	0.00362	CbGpPWpGaD
Norethindrone—Nausea—Prednisone—chronic obstructive pulmonary disease	6.72e-05	0.000754	CcSEcCtD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	6.67e-05	0.00354	CbGpPWpGaD
Norethindrone—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	6.66e-05	0.00354	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	6.58e-05	0.0035	CbGpPWpGaD
Norethindrone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	6.51e-05	0.00346	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	6.48e-05	0.00344	CbGpPWpGaD
Norethindrone—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.42e-05	0.00341	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	6.28e-05	0.00334	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—CTGF—chronic obstructive pulmonary disease	6.01e-05	0.00319	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.01e-05	0.00319	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—CRP—chronic obstructive pulmonary disease	5.96e-05	0.00317	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.94e-05	0.00315	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	5.87e-05	0.00312	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	5.77e-05	0.00306	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.76e-05	0.00306	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.68e-05	0.00302	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—SERPINE1—chronic obstructive pulmonary disease	5.63e-05	0.00299	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	5.51e-05	0.00293	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	5.39e-05	0.00286	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	5.38e-05	0.00286	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	5.32e-05	0.00282	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.29e-05	0.00281	CbGpPWpGaD
Norethindrone—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.28e-05	0.0028	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.22e-05	0.00277	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	5.14e-05	0.00273	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	5.11e-05	0.00271	CbGpPWpGaD
Norethindrone—CYP3A7—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.02e-05	0.00267	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.99e-05	0.00265	CbGpPWpGaD
Norethindrone—CYP3A7—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.95e-05	0.00263	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.92e-05	0.00261	CbGpPWpGaD
Norethindrone—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	4.84e-05	0.00257	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	4.76e-05	0.00253	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	4.73e-05	0.00252	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SERPINE2—chronic obstructive pulmonary disease	4.7e-05	0.00249	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	4.64e-05	0.00247	CbGpPWpGaD
Norethindrone—Progesterone—CYP1A1—chronic obstructive pulmonary disease	4.61e-05	0.23	CrCbGaD
Norethindrone—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.59e-05	0.00244	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—SERPINE1—chronic obstructive pulmonary disease	4.58e-05	0.00243	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—SERPINA1—chronic obstructive pulmonary disease	4.57e-05	0.00243	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IL1B—chronic obstructive pulmonary disease	4.57e-05	0.00243	CbGpPWpGaD
Norethindrone—Progesterone—CYP1A2—chronic obstructive pulmonary disease	4.45e-05	0.222	CrCbGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	4.37e-05	0.00232	CbGpPWpGaD
Norethindrone—Testosterone—CYP1A1—chronic obstructive pulmonary disease	4.36e-05	0.218	CrCbGaD
Norethindrone—Methyltestosterone—ALB—chronic obstructive pulmonary disease	4.18e-05	0.209	CrCbGaD
Norethindrone—CYP3A5—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.16e-05	0.00221	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.11e-05	0.00218	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—RAPGEF3—chronic obstructive pulmonary disease	4.11e-05	0.00218	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—EGFR—chronic obstructive pulmonary disease	4.1e-05	0.00218	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—APIP—chronic obstructive pulmonary disease	4.04e-05	0.00214	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	4.01e-05	0.00213	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—TGFB2—chronic obstructive pulmonary disease	3.97e-05	0.00211	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.93e-05	0.00209	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—SERPINE1—chronic obstructive pulmonary disease	3.92e-05	0.00208	CbGpPWpGaD
Norethindrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	3.92e-05	0.00208	CbGpPWpGaD
Norethindrone—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	3.86e-05	0.00205	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.86e-05	0.00205	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.83e-05	0.00203	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.81e-05	0.00202	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.77e-05	0.002	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—chronic obstructive pulmonary disease	3.74e-05	0.00199	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL1B—chronic obstructive pulmonary disease	3.72e-05	0.00198	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	3.64e-05	0.00193	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.64e-05	0.00193	CbGpPWpGaD
Norethindrone—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.63e-05	0.00193	CbGpPWpGaD
Norethindrone—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.58e-05	0.0019	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—TNF—chronic obstructive pulmonary disease	3.32e-05	0.00176	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.26e-05	0.00173	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.22e-05	0.00171	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.17e-05	0.00169	CbGpPWpGaD
Norethindrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.17e-05	0.00169	CbGpPWpGaD
Norethindrone—PGR—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	3.15e-05	0.00167	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.98e-05	0.00158	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.96e-05	0.00157	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	2.95e-05	0.00157	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	2.94e-05	0.00156	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	2.92e-05	0.00155	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.92e-05	0.00155	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—CTGF—chronic obstructive pulmonary disease	2.9e-05	0.00154	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	2.82e-05	0.0015	CbGpPWpGaD
Norethindrone—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.8e-05	0.00149	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	2.79e-05	0.00148	CbGpPWpGaD
Norethindrone—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.77e-05	0.00147	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.76e-05	0.00147	CbGpPWpGaD
Norethindrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	2.76e-05	0.00147	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—SERPINE1—chronic obstructive pulmonary disease	2.74e-05	0.00146	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	2.7e-05	0.00143	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TNF—chronic obstructive pulmonary disease	2.7e-05	0.00143	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—HDAC2—chronic obstructive pulmonary disease	2.7e-05	0.00143	CbGpPWpGaD
Norethindrone—ALB—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	2.68e-05	0.00142	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.67e-05	0.00142	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	2.6e-05	0.00138	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	2.57e-05	0.00137	CbGpPWpGaD
Norethindrone—ALB—Metabolism—APIP—chronic obstructive pulmonary disease	2.51e-05	0.00133	CbGpPWpGaD
Norethindrone—ALB—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	2.48e-05	0.00132	CbGpPWpGaD
Norethindrone—Testosterone—ALB—chronic obstructive pulmonary disease	2.43e-05	0.121	CrCbGaD
Norethindrone—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.42e-05	0.00128	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.4e-05	0.00127	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	2.39e-05	0.00127	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—chronic obstructive pulmonary disease	2.38e-05	0.00126	CbGpPWpGaD
Norethindrone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	2.36e-05	0.00125	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	2.36e-05	0.00125	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.32e-05	0.00123	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.29e-05	0.00122	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	2.26e-05	0.0012	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	2.2e-05	0.00117	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	2.19e-05	0.00116	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	2.18e-05	0.00116	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	2.14e-05	0.00114	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	2.05e-05	0.00109	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	2.04e-05	0.00109	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.94e-05	0.00103	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.93e-05	0.00103	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.91e-05	0.00101	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	1.88e-05	0.000999	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	1.83e-05	0.000974	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.79e-05	0.000952	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.78e-05	0.000945	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.75e-05	0.000932	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.75e-05	0.000932	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.75e-05	0.000928	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	1.74e-05	0.000925	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.73e-05	0.000919	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.69e-05	0.000896	CbGpPWpGaD
Norethindrone—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.66e-05	0.000884	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.66e-05	0.000883	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.65e-05	0.000878	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.65e-05	0.000877	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.63e-05	0.000866	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GC—chronic obstructive pulmonary disease	1.62e-05	0.00086	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.61e-05	0.000854	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.51e-05	0.0008	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.5e-05	0.000799	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.49e-05	0.000794	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.48e-05	0.000787	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.46e-05	0.000775	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.45e-05	0.000772	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.42e-05	0.000755	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.42e-05	0.000754	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	1.4e-05	0.000746	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.36e-05	0.000721	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.35e-05	0.000718	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.34e-05	0.000714	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—SERPINE1—chronic obstructive pulmonary disease	1.32e-05	0.000701	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.32e-05	0.000701	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.29e-05	0.000686	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	1.28e-05	0.000681	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.22e-05	0.000649	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.2e-05	0.000637	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	1.2e-05	0.000636	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.18e-05	0.000628	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.18e-05	0.000627	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.18e-05	0.000626	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.18e-05	0.000625	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.16e-05	0.000616	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.13e-05	0.000601	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.1e-05	0.000584	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.09e-05	0.000581	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.08e-05	0.000575	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.08e-05	0.000572	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.07e-05	0.000566	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.06e-05	0.000564	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.03e-05	0.000546	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.02e-05	0.000539	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.01e-05	0.000537	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.85e-06	0.000523	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.71e-06	0.000516	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	9.26e-06	0.000492	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.05e-06	0.000481	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.98e-06	0.000477	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	8.97e-06	0.000477	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	8.91e-06	0.000473	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.84e-06	0.00047	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	8.74e-06	0.000464	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	8.74e-06	0.000464	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.58e-06	0.000456	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.58e-06	0.000456	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	8.57e-06	0.000455	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.54e-06	0.000453	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.19e-06	0.000435	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.13e-06	0.000432	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	7.98e-06	0.000424	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.94e-06	0.000422	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	7.85e-06	0.000417	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.75e-06	0.000412	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	7.66e-06	0.000407	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.35e-06	0.00039	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.32e-06	0.000389	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.27e-06	0.000386	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	7.16e-06	0.00038	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.12e-06	0.000378	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.02e-06	0.000373	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	6.99e-06	0.000371	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.79e-06	0.000361	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.6e-06	0.000351	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.57e-06	0.000349	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.54e-06	0.000348	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.44e-06	0.000342	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.2e-06	0.000329	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	6.17e-06	0.000328	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.13e-06	0.000326	CbGpPWpGaD
Norethindrone—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.05e-06	0.000321	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.9e-06	0.000314	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	5.83e-06	0.00031	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.66e-06	0.000301	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.63e-06	0.000299	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	5.58e-06	0.000296	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.5e-06	0.000292	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.43e-06	0.000288	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.42e-06	0.000288	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.37e-06	0.000285	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.34e-06	0.000284	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.31e-06	0.000282	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.3e-06	0.000281	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.06e-06	0.000269	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.94e-06	0.000262	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.79e-06	0.000255	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.77e-06	0.000254	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.72e-06	0.000251	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.68e-06	0.000249	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	4.66e-06	0.000248	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.46e-06	0.000237	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.31e-06	0.000229	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	4.22e-06	0.000224	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.08e-06	0.000217	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	4.03e-06	0.000214	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.97e-06	0.000211	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	3.47e-06	0.000184	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.31e-06	0.000176	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.26e-06	0.000173	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.26e-06	0.000173	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.18e-06	0.000169	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	3.12e-06	0.000166	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.04e-06	0.000162	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.04e-06	0.000162	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.88e-06	0.000153	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.96e-06	0.000104	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.87e-06	9.96e-05	CbGpPWpGaD
